BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 20676058)

  • 1. Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains.
    Reynoird N; Schwartz BE; Delvecchio M; Sadoul K; Meyers D; Mukherjee C; Caron C; Kimura H; Rousseaux S; Cole PA; Panne D; French CA; Khochbin S
    EMBO J; 2010 Sep; 29(17):2943-52. PubMed ID: 20676058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanistic analysis of the role of bromodomain-containing protein 4 (BRD4) in BRD4-NUT oncoprotein-induced transcriptional activation.
    Wang R; You J
    J Biol Chem; 2015 Jan; 290(5):2744-58. PubMed ID: 25512383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma.
    Alekseyenko AA; Walsh EM; Zee BM; Pakozdi T; Hsi P; Lemieux ME; Dal Cin P; Ince TA; Kharchenko PV; Kuroda MI; French CA
    Proc Natl Acad Sci U S A; 2017 May; 114(21):E4184-E4192. PubMed ID: 28484033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perturbation of BRD4 protein function by BRD4-NUT protein abrogates cellular differentiation in NUT midline carcinoma.
    Yan J; Diaz J; Jiao J; Wang R; You J
    J Biol Chem; 2011 Aug; 286(31):27663-75. PubMed ID: 21652721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma.
    Zhang X; Zegar T; Lucas A; Morrison-Smith C; Knox T; French CA; Knapp S; Müller S; Siveke JT
    Oncogene; 2020 Jun; 39(24):4770-4779. PubMed ID: 32366905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Supercharging BRD4 with NUT in carcinoma.
    Eagen KP; French CA
    Oncogene; 2021 Feb; 40(8):1396-1408. PubMed ID: 33452461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural mechanism of BRD4-NUT and p300 bipartite interaction in propagating aberrant gene transcription in chromatin in NUT carcinoma.
    Yu D; Liang Y; Kim C; Jaganathan A; Ji D; Han X; Yang X; Jia Y; Gu R; Wang C; Zhang Q; Cheung KL; Zhou MM; Zeng L
    Nat Commun; 2023 Jan; 14(1):378. PubMed ID: 36690674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
    Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
    Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brd4's Bromodomains Mediate Histone H3 Acetylation and Chromatin Remodeling in Pluripotent Cells through P300 and Brg1.
    Wu T; Kamikawa YF; Donohoe ME
    Cell Rep; 2018 Nov; 25(7):1756-1771. PubMed ID: 30428346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains.
    Alekseyenko AA; Walsh EM; Wang X; Grayson AR; Hsi PT; Kharchenko PV; Kuroda MI; French CA
    Genes Dev; 2015 Jul; 29(14):1507-23. PubMed ID: 26220994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells.
    French CA; Ramirez CL; Kolmakova J; Hickman TT; Cameron MJ; Thyne ME; Kutok JL; Toretsky JA; Tadavarthy AK; Kees UR; Fletcher JA; Aster JC
    Oncogene; 2008 Apr; 27(15):2237-42. PubMed ID: 17934517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma.
    French CA; Miyoshi I; Kubonishi I; Grier HE; Perez-Atayde AR; Fletcher JA
    Cancer Res; 2003 Jan; 63(2):304-7. PubMed ID: 12543779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical Screen Identifies Diverse and Novel Histone Deacetylase Inhibitors as Repressors of NUT Function: Implications for NUT Carcinoma Pathogenesis and Treatment.
    Shiota H; Alekseyenko AA; Wang ZA; Filic I; Knox TM; Luong NM; Huang Y; Scott DA; Jones KL; Gokhale PC; Lemieux ME; Cole PA; Kuroda MI; French CA
    Mol Cancer Res; 2021 Nov; 19(11):1818-1830. PubMed ID: 34285087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation.
    Thomas MC; Chiang CM
    Mol Cell; 2005 Jan; 17(2):251-64. PubMed ID: 15664194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNAs interact with BRD4 to promote enhanced chromatin engagement and transcription activation.
    Rahnamoun H; Lee J; Sun Z; Lu H; Ramsey KM; Komives EA; Lauberth SM
    Nat Struct Mol Biol; 2018 Aug; 25(8):687-697. PubMed ID: 30076409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential contribution of p300 and CBP to regulatory element acetylation in mESCs.
    Martire S; Nguyen J; Sundaresan A; Banaszynski LA
    BMC Mol Cell Biol; 2020 Jul; 21(1):55. PubMed ID: 32690000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation.
    Wu SY; Chiang CM
    J Biol Chem; 2007 May; 282(18):13141-5. PubMed ID: 17329240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of SOX2 expression by BRD4-NUT oncogenic fusion drives neoplastic transformation in NUT midline carcinoma.
    Wang R; Liu W; Helfer CM; Bradner JE; Hornick JL; Janicki SM; French CA; You J
    Cancer Res; 2014 Jun; 74(12):3332-43. PubMed ID: 24736545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of Lef-mediated transcription and p53-dependent pathway by associating beta-catenin with CBP/p300.
    Miyagishi M; Fujii R; Hatta M; Yoshida E; Araya N; Nagafuchi A; Ishihara S; Nakajima T; Fukamizu A
    J Biol Chem; 2000 Nov; 275(45):35170-5. PubMed ID: 10906119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NUT Is a Driver of p300-Mediated Histone Hyperacetylation: From Spermatogenesis to Cancer.
    Rousseaux S; Reynoird N; Khochbin S
    Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.